Stock AnalizCeribell, Inc. CBLL
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2024 · data as of November 13, 2026
Ceribell, Inc. (CBLL) is a healthcare company listed in the US with a market value of about $1.0B. In the twelve months to September 30, 2026 it had revenue of $109M and net income of -$74M, a net margin of -68.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -26%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $109M | $89M | $65M | $45M |
| Net income | -$74M | -$53M | -$40M | -$29M |
| Free cash flow | -$56M | -$42M | -$36M | -$30M |
| EPS (diluted) | $-1.94 | $-1.46 | $-3.39 | $-5.56 |
| Net margin | -68.0% | -60.0% | -61.8% | -65.1% |
| ROIC | — | -32.9% | -18.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $31.57, 21% above the current price; targets range from $30.00 to $33.00; the consensus rating is “Strong buy”; expected EPS is $-2.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Ceribell stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ceribell pay a dividend?
Not currently.
Is Ceribell a good stock to buy?
We do not give buy or sell advice. Ceribell scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.